Feeds:
Posts
Comments

Archive for January, 2010

TODAY’S NEWS Pfizer and Merck – top sales forces, and overcharging New York. Harrison Ford and a movie about a biotech company. Not the next Avatar with ticket sales, apparently. Big Pharma’s messy pipeline. RECOMMENDED Simulations for training – “Live” simulations or eLearning experiences – our preferred partners can provide what you need. Contact us [...]

Read Full Post »

TODAY’S NEWS Pfizer trimming pipeline projects after Wyeth acquisition – Pfizer Inc., the world’s biggest drugmaker, said Wednesday it is quitting plans to sell popular pain drug Lyrica as an add-on treatment for anxiety as it shaves about 100 projects from its combined portfolio after swallowing rival Wyeth…more AstraZeneca: 8,000 more cuts coming. Ouch – [...]

Read Full Post »

Apple just yesterday introduced the iPad, essentially an iPhone on steroids that bridges the gap between smartphones and small computers. Will this be the platform that accelerates eHealthcare on the provider side (hospitals, doctors, medical education, etc.)? I say yes. Here’s why: First of all, the pace at which doctors are using smartphones as part [...]

Read Full Post »

TODAY’S NEWS Merck losing Temodar patent battle with Teva – A federal court judge ruled Tuesday that a patent for Merck & Co. Inc.‘s Temodar is unenforceable, allowing Teva Pharmaceuticals USA Inc. to sell a generic version of the chemotherapy drug. Israel-based Teva, the world’s largest generic drug maker, is seeking FDA approval to sell [...]

Read Full Post »

TODAY’S NEWS Big change – Dan Vasella to step aside as Novartis CEO. This article also details the other internal leadership changes – very interesting. Novo Nordisk gets approval for new diabetes drug Victoza – Federal health officials on Monday approved Danish drugmaker Novo Nordisk’s once-daily injection for treating type 2 diabetes but said more [...]

Read Full Post »

TODAY’S NEWS Pfizer‘s oncology drug Sutent slows down pancreatic cancer spread – Pfizer Inc.  said Sutent, its drug for kidney cancer, also helps stop the progression of a kind of pancreatic cancer, according to a late-stage trial. Sutent is in several late-stage studies to investigate expanding its use beyond kidney and gastrointestinal treatment, exploring its [...]

Read Full Post »

TODAY’S NEWS Note: if you’re going to engage in questionable marketing practices, documenting it in Powerpoint is probably not a “best practice”! Just saying… Experiment HIV drug from Merck fails in late-stage studies – Merck & Co  on Wednesday said its experimental HIV treatment vicriviroc proved ineffective in two late-stage studies involving patients who had [...]

Read Full Post »

Impactiviti Daily 011810

TODAY’S NEWS Pharma’s responses to the disaster in Haiti – good to see. Novartis investing in “smart pills” – Novartis is ramping up its commitment to personalized medicine with a $24 million investment in Proteus Biomedical, a pioneer of high-tech pills featuring embedded ingestible sensors. Smart pills are a hot technology in the never-ending quest [...]

Read Full Post »

Impactiviti Daily 011510

TODAY’S NEWS Pfizer‘s Chantix (smoke cessation product) under more legal fire for attempted suicides, deaths. Amgen‘s new drug hopes – Amgen Inc.’s 15-year search for a way to strengthen weak bones led scientists to a medicine that may stop tumors from spreading beyond soft tissue. The discovery may also help revive the company’s fortunes. U.S. [...]

Read Full Post »

TODAY’S NEWS How to do dumb insider trading – a lesson. Experimental Plavix competitor Brilinta showing improved efficacy in ACS stent patients. Enbrel competitor Stelera shows greater efficacy in psoriasis treatment. Obesity leveling off in U.S., but Diabetes is killing the economy. RECOMMENDED Management development. From full curriculum planning to workshops to targeted courses, we [...]

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.